Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

560 recalls, newest first

Class III · Low risk

Revcovi (elapegademase-lvlr)

Failed Stability Specifications: Out of specification stability result for the protein concentration profile.

Ongoing Stability / shelf life Chiesi USA, Inc. NDC 10122-502-01 D-0838-2026
Class I · High risk

Dextrose Injection

Presence of Particulate Matter: particulate matter identified as stainless steel particles in the solution.

Ongoing Particulate / foreign matter Baxter Healthcare Corporation NDC 00338-0719-06 D-0850-2026
Class II · Moderate risk

Prasugrel Tablets

Failed Dissolution Specifications; product failed to meet 18-month stability testing acceptance criteria

Ongoing Dissolution failure Mylan Pharmaceuticals Inc NDC 0378-5186-93 D-0839-2026
Class II · Moderate risk

Paxil CR

Failed Dissolution Specifications; product failed to meet 24-month stability testing acceptance criteria

Ongoing Dissolution failure Apotex Corp. NDC 60505-4379-3 D-0804-2026
Class I · High risk

Epinephrine Injection

Presence of Particulate Matter and Lack of Assurance of Sterility. Particulate matter identified as nylon, cellulosic, acrylic, polyethylene and glass and broken and leaking vials.

Ongoing Sterility / contamination American Regent, Inc. NDC 0517-3030-01 D-0865-2026
Class I · High risk

Tyenne (tocilizumab-aazg)

Presence of particulate matter:An internal investigation at the firm found the product to contain glass particles.

Ongoing Particulate / foreign matter Fresenius Kabi USA, LLC NDC 65219-594-20 D-0827-2026

Recalls by year